×
About 50 results

ALLMedicine™ Anaplastic Ganglioglioma Center

Research & Reviews  19 results

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT03919071

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplast...

Uncommon Glioneuronal Tumors: A Radiologic and Pathologic Synopsis.
https://doi.org/10.3174/ajnr.A7465
AJNR. American Journal of Neuroradiology; Vaz A, Cavalcanti MS et. al.

May 6th, 2022 - Glioneuronal tumors are characterized exclusively by neurocytic elements (neuronal tumors) or a combination of neuronal and glial features (mixed neuronal-glial tumors). Most of these tumors occur in young patients and are related to epilepsy. Whi...

Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grad...
https://doi.org/10.1093/neuonc/noac096
Neuro-oncology Rosenberg T, Yeo KK et. al.

Apr 10th, 2022 - The prognosis for patients with pediatric high-grade glioma (pHGG) is poor despite aggressive multi-modal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients with recurrent BRAF-mutant pHGG but...

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972326
Neuro-oncology Andrews LJ, Thornton ZA et. al.

Nov 1st, 2021 - Detailed prevalence estimates of BRAFV600 mutations and BRAF inhibitor (BRAFi) treatment responses in V600-mutant glioma will inform trial development. Our systematic review analyzed overall prevalence of BRAFV600 mutations in glioma and BRAFi tre...

see more →

Clinicaltrials.gov  1 results

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT03919071

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplast...

see more →